Astellas Pharma US Release: Data on MYRBETRIQ® (mirabegron) as Treatment for Overactive Bladder Presented at American Urological Association 2013
5/8/2013 7:06:11 AM
More...
|
Tokyo Institute of Technology and Astellas Pharma Inc. (YPH.BE) Launch Collaborative Research for New Anti-Dengue Virus Drugs for Neglected Tropical Diseases
3/21/2013 10:45:11 AM
More...
|
Astellas Pharma Inc. (YPH.BE) and Ambit Biosciences to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
3/12/2013 6:48:51 AM
More...
|
Medivation, Inc. (MDVN) and Astellas Pharma US Provide Additional Support to Metastatic Prostate Cancer Patients Through Donations to Independent Non-Profit Patient Assistance Organization
2/26/2013 9:39:45 AM
More...
|
PGA TOUR Celebrates Official Launch of the Astellas Pharma US Presents Executive Women's Day Program
2/26/2013 9:33:35 AM
More...
|
Astellas Pharma US to Drive PGA TOUR's New Women's Initiative
2/19/2013 12:47:34 PM
More...
|
Astellas Pharma US Highlights Progress to Advance Care of Patients with Genitourinary Cancers at American Society of Clinical Oncology-GU Annual Meeting
2/13/2013 9:45:47 AM
More...
|
Astellas Pharma US' New Headquarters for the Americas Awarded LEED Gold Certification
1/22/2013 10:33:30 AM
More...
|
Astellas Pharma US Release: FDA Accepts Supplemental New Drug Application for Tarceva® (erlotinib) Tablets for Genetically Distinct Form of Advanced Lung Cancer
1/16/2013 9:22:31 AM
More...
|
Astellas Pharma US Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
12/5/2012 9:00:05 AM
More...
|
|